EA201992704A1 - Новое применение агониста формил-пептидного рецептора 2/рецептора липоксина a4 (fpr2/alx) для лечения сердечной недостаточности - Google Patents

Новое применение агониста формил-пептидного рецептора 2/рецептора липоксина a4 (fpr2/alx) для лечения сердечной недостаточности

Info

Publication number
EA201992704A1
EA201992704A1 EA201992704A EA201992704A EA201992704A1 EA 201992704 A1 EA201992704 A1 EA 201992704A1 EA 201992704 A EA201992704 A EA 201992704A EA 201992704 A EA201992704 A EA 201992704A EA 201992704 A1 EA201992704 A1 EA 201992704A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
heart failure
formil
fpr2
lipoxin
Prior art date
Application number
EA201992704A
Other languages
English (en)
Russian (ru)
Inventor
Ясек Островский
Рикардо Гарсиа
Николас Р. Вуртц
Нэнси Ли Карсон
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201992704(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201992704A1 publication Critical patent/EA201992704A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201992704A 2017-05-22 2018-05-22 Новое применение агониста формил-пептидного рецептора 2/рецептора липоксина a4 (fpr2/alx) для лечения сердечной недостаточности EA201992704A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (1)

Publication Number Publication Date
EA201992704A1 true EA201992704A1 (ru) 2020-03-19

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992704A EA201992704A1 (ru) 2017-05-22 2018-05-22 Новое применение агониста формил-пептидного рецептора 2/рецептора липоксина a4 (fpr2/alx) для лечения сердечной недостаточности

Country Status (15)

Country Link
US (1) US20200069644A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020520948A (cg-RX-API-DMAC7.html)
KR (1) KR20200006595A (cg-RX-API-DMAC7.html)
CN (1) CN110662538A (cg-RX-API-DMAC7.html)
AU (1) AU2018273382A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019024185A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003325A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013015A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992704A1 (cg-RX-API-DMAC7.html)
IL (1) IL270749A (cg-RX-API-DMAC7.html)
MX (1) MX2019013926A (cg-RX-API-DMAC7.html)
PE (1) PE20200402A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018217684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
EP4178946A1 (en) 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
ES2986512T3 (es) 2020-07-09 2024-11-11 Bristol Myers Squibb Co Agonistas del receptor 2 del péptido formil pirazolona
WO2022035923A1 (en) 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
WO2022076764A1 (en) * 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Aminoimidazole fpr2 agonists
CN119055775A (zh) * 2022-07-30 2024-12-03 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療
EP3305763B1 (en) * 2013-11-28 2019-07-24 Kyorin Pharmaceutical Co., Ltd. Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists
KR101645015B1 (ko) * 2014-03-11 2016-08-03 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
AU2018273382A1 (en) 2020-01-16
IL270749A (en) 2020-01-30
EP3630097A1 (en) 2020-04-08
CL2019003325A1 (es) 2020-04-17
CO2019013015A2 (es) 2020-01-17
BR112019024185A2 (pt) 2020-06-02
MX2019013926A (es) 2020-01-20
WO2018217684A1 (en) 2018-11-29
CN110662538A (zh) 2020-01-07
KR20200006595A (ko) 2020-01-20
CA3064291A1 (en) 2018-11-29
US20200069644A1 (en) 2020-03-05
PE20200402A1 (es) 2020-02-26
JP2020520948A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2019013926A (es) Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca.
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
SA520420468B1 (ar) مركبات تثبيط كيناز بروتين-1 يتداخل مع مستقبل وطرق لتحضير واستخدامها
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
JOP20190175A1 (ar) مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR)
CL2016002497A1 (es) “compuestos derivados de heterociclos condensados sustituidos, moduladores de gpr119; composición farmacéutica que los comprende; útiles en el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados”. pct
MX2020007898A (es) Moduladores de cinasa de proteina asociada con rho.
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
NO20090624L (no) Forbindelser som modulerer CB2 receptoren
EA201171063A1 (ru) Фармацевтические составы олмесартана
MX2018006635A (es) Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona.
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
MX2019008993A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
MX378160B (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA202091428A1 (ru) Замещенные амиды ii пирролидина
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
EA201991898A1 (ru) Двойные ингибиторы magl и faah
CY1125333T1 (el) Μεθοδος παρασκευης μιας κρυσταλλικης μορφης της μηλεϊνικης 1-((2r, 4r)-2- (1h-benzo[d] ιμιδαζολ-2- υλο)-1-μεθυλο-πιπεριδιν-4-υλο)-3-(4- κυανοφαινυλ)ουριας· μια κρυσταλλικη μορφη συμπλοκου 1-((2r, 4r)-2- (1h-benzo[d] ιμιδαζολ-2- υλο)-1-μεθυλοπιπεριδιν-4-υλο)-3-(4-κυανοφαινυλ) ουριας ιμιδαζολης (1:1)
EP4480485A3 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
WO2019054891A3 (en) Trpv2 antagonists
PH12021550055A1 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MX2023005716A (es) Derivados de cromeno como inhibidores de la interaccion receptor de antigeno de celula t (tcr) - region no catalitica de la proteina citosolica de la proteina tirosina cinasa (nck).